ILC Therapeutics

ILC Therapeutics is a pioneering pharmaceutical manufacturing company dedicated to developing innovative hybrid interferons, representing a new class of engineered drugs with enhanced therapeutic profiles. ILC Therapeutics focuses on creating solutions applicable across a broad spectrum of indications. Their unique platform combines the beneficial attributes of specific natural interferon sub-types, resulting in novel drug candidates designed for reduced toxicity and improved efficacy.

Based in Glasgow, ILC Therapeutics' primary address is Spaces, 100 West George Street, Glasgow, G2 1PP, GB. ILC Therapeutics is committed to advancing healthcare through cutting-edge research and development. The company's first-in-class lead candidates, Alfacyte™ and Dermacyte™, are focused on antiviral and dermatological indications, respectively, and are progressing towards clinical trials. The entire team at ILC Therapeutics is dedicated to improving patient outcomes and advancing the future of medicine.

ILC Therapeutics continues to expand its research and development efforts, striving to bring groundbreaking treatments to market. We invite the manager of ILC Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their innovative work.